BRIVIACT add-on treatment of partial-onset seizures

Click2Contact

Now available on the PBS, BRIVIACT (brivaracetam) is an add-on therapy for the treatment of partial-onset seizures (POS) with or without secondary generalisation in patients from 16 years of age with epilepsy.

Independent research has shown that adjunct use of brivaracetam 100 mg/day was associated with a 22.8% reduction in 28-day adjusted seizure frequency over the placebo (p<0.001). Across three clinical trials, over 12 weeks, POS were more than halved in 39.5% of patients treated with brivaracetam 100 mg/day.

Brivaracetam was found to display a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, thought to be its primary mechanism for its anticonvulsant effect. Brivaracetam was generally well tolerated; commonly reported adverse events (>5%) were somnolence (15.2%), dizziness (11.2%), headache (9.6%) and fatigue (8.7%) and were usually mild to moderate.